Sanofi/Regeneron's sarilumab hits first PhIII arthritis endpoints
This article was originally published in Scrip
Sarilumab, Sanofi and Regeneron Pharmaceuticals' experimental antibody drug, has met its three primary endpoints in a Phase III trial in rheumatoid arthritis. The product was shown to be effective in patients with active, moderate to severe disease, who had responded inadequately to methotrexate therapy, both improving disease signs and symptoms and inhibiting the progression of joint damage.
You may also be interested in...
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.